Sarepta Therapeutics (SRPT) Change in Cash (2016 - 2025)
Sarepta Therapeutics has reported Change in Cash over the past 15 years, most recently at $188.2 million for Q4 2025.
- Quarterly results put Change in Cash at $188.2 million for Q4 2025, down 79.21% from a year ago — trailing twelve months through Dec 2025 was -$304.2 million (down 145.09% YoY), and the annual figure for FY2025 was -$304.2 million, down 145.09%.
- Change in Cash for Q4 2025 was $188.2 million at Sarepta Therapeutics, up from $100.0 million in the prior quarter.
- Over the last five years, Change in Cash for SRPT hit a ceiling of $905.2 million in Q4 2024 and a floor of -$882.0 million in Q1 2022.
- Median Change in Cash over the past 5 years was -$32.2 million (2021), compared with a mean of -$34.9 million.
- Biggest five-year swings in Change in Cash: skyrocketed 1714.55% in 2021 and later plummeted 75526.58% in 2025.
- Sarepta Therapeutics' Change in Cash stood at $517.3 million in 2021, then tumbled by 113.89% to -$71.8 million in 2022, then tumbled by 62.95% to -$117.1 million in 2023, then skyrocketed by 873.16% to $905.2 million in 2024, then plummeted by 79.21% to $188.2 million in 2025.
- The last three reported values for Change in Cash were $188.2 million (Q4 2025), $100.0 million (Q3 2025), and $269.7 million (Q2 2025) per Business Quant data.